How much of Pfizer's 1994 earnings improvement came from underlying operations rather than the prior-year charge?

Much of the headline 97% net income increase reflects the absence of the 1993 $750 million restructuring charge. On an ongoing basis, net income grew about 10% and EPS about 13%. Ongoing pre-tax income rose $258.1 million, reflecting strong pharmaceutical growth and a better production margin (76.8% of sales, up from 72% in 1992).

Which products are driving Pfizer's growth, and how concentrated is that growth?

Growth is concentrated in newer pharmaceuticals. Norvasc sales rose 85%, Zoloft 55%, Zithromax 43%, and Cardura 27%. Procardia XL, the largest single product with about $1.2 billion in sales, was flat, and Feldene and Glucotrol declined as generic competition arrived. Cardiovascular products are the largest therapeutic category at 29% of sales.

What are the main financial risks investors should watch?

Leverage rose sharply, with debt-to-capitalization up to 40% and short-term borrowings at $2.2 billion, partly to fund the SmithKline Beecham animal health acquisition. The Procardia XL patent is protected until 2003, but mature products face generic erosion. U.S. pricing pressure from managed care and government rebate requirements is expected to continue into 1995. Foreign exchange exposure is significant, with 47% of sales outside the U.S.

Is the Shiley heart valve litigation a material risk?

Pfizer describes the Shiley C/C heart valve claims as a major legal matter. A worldwide settlement class was approved in 1992 and upheld on appeal, and most costs are expected to be covered by insurance and proceeds from the 1992 sale of Shiley product lines. Roughly 900 opt-out implantees were involved, with about 792 resolved. A separate shareholder class action and insurance coverage disputes are pending. Management believes these should not have a material adverse effect, though outcomes remain uncertain.

PFE 10-K FY1994 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 24, 1995. Cited figures are marked; the original filing is the authoritative source.

Pfizer's 1994 Form 10-K shows a company in strong operating recovery after a difficult 1993.

Net sales rose 11% to $8.28 billion, and net income more than doubled to $1.30 billion^a ($4.19 per share) from $657.5 million ($2.05 per share) in 1993. The 1993 figure carried a $750 million restructuring charge, so on an ongoing basis net income grew about 10% and EPS about 13%. Growth was driven almost entirely by volume from newer pharmaceuticals.

Pharmaceuticals reached 70% of sales, and the six launched-in-the-1990s products (Norvasc, Diflucan, Zoloft, Cardura, Zithromax, Glucotrol XL) grew 44% and represented 33% of sales. Research and development spending rose 17% to $1.14 billion^b, with about $1.4 billion planned for 1995, which signals continued investment in the pipeline. The balance sheet and cash flow picture is more mixed.

Operating cash flow was a solid $1.49 billion^c, but debt-to-total-capitalization rose to 40% from 31%, largely from share repurchases and increased short-term borrowings. Short-term borrowings reached $2.2 billion. Early 1995 brought significant transactions: the roughly $1.45 billion acquisition of SmithKline Beecham's animal health business, a planned $175 million NAMIC acquisition, and a proposed two-for-one stock split.

Pfizer also reported a dividend increase of 11%^d for 1995, its 28th consecutive annual increase, and maintained Aaa/AAA credit ratings. Key risks flagged in the filing include exposure to generic competition as Feldene and Glucotrol mature, pressure on U.S. pricing from managed care and rebate legislation, uncertainty around health care reform, and significant litigation.

The most prominent litigation involves Shiley C/C heart valves, along with asbestos, antitrust suits from retail pharmacies, and penile prosthesis class actions. Management states that none of these is expected to have a material adverse effect, though the Shiley and product liability matters remain the main sources of uncertainty.

02—Key points

Key Highlights

Net sales increased 11% to $8,281.3 million in 1994, driven entirely by volume growth, with no price contribution.
Net income rose to $1,298.4 million ($4.19 per share) from $657.5 million in 1993, which included a $750 million restructuring charge; ongoing EPS grew about 13%.
Pharmaceutical products represented 70% of consolidated sales; the six products launched in the 1990s grew 44% and accounted for 33% of net sales.
R&D expenditures rose 17% to $1.14 billion, and the company plans about $1.4 billion in 1995 R&D spending.
Debt-to-total-capitalization increased to 40% from 31%, driven by share buybacks and higher short-term borrowings; senior debt remains rated Aaa/AAA.
Early-1995 acquisitions include SmithKline Beecham's animal health business (~$1.45 billion) and NAMIC U.S.A. (~$175 million), and the board proposed a two-for-one stock split plus an 11% dividend increase.
Key risks include generic competition for Feldene and Glucotrol, U.S. managed care and rebate pressures, health care reform uncertainty, and ongoing Shiley heart valve and asbestos litigation.

03—Questions

Frequently Asked Questions

How much of Pfizer's 1994 earnings improvement came from underlying operations rather than the prior-year charge?
Much of the headline 97% net income increase reflects the absence of the 1993 $750 million restructuring charge. On an ongoing basis, net income grew about 10% and EPS about 13%. Ongoing pre-tax income rose $258.1 million, reflecting strong pharmaceutical growth and a better production margin (76.8% of sales, up from 72% in 1992).
Which products are driving Pfizer's growth, and how concentrated is that growth?
Growth is concentrated in newer pharmaceuticals. Norvasc sales rose 85%, Zoloft 55%, Zithromax 43%, and Cardura 27%. Procardia XL, the largest single product with about $1.2 billion in sales, was flat, and Feldene and Glucotrol declined as generic competition arrived. Cardiovascular products are the largest therapeutic category at 29% of sales.
What are the main financial risks investors should watch?
Leverage rose sharply, with debt-to-capitalization up to 40% and short-term borrowings at $2.2 billion, partly to fund the SmithKline Beecham animal health acquisition. The Procardia XL patent is protected until 2003, but mature products face generic erosion. U.S. pricing pressure from managed care and government rebate requirements is expected to continue into 1995. Foreign exchange exposure is significant, with 47% of sales outside the U.S.
Is the Shiley heart valve litigation a material risk?
Pfizer describes the Shiley C/C heart valve claims as a major legal matter. A worldwide settlement class was approved in 1992 and upheld on appeal, and most costs are expected to be covered by insurance and proceeds from the 1992 sale of Shiley product lines. Roughly 900 opt-out implantees were involved, with about 792 resolved. A separate shareholder class action and insurance coverage disputes are pending. Management believes these should not have a material adverse effect, though outcomes remain uncertain.

04—Continue

← View all 10-K filings